Well, Advaxis did put it out there that the HOT NSCLC trial would start before the end of the year. That trial will be the HOT construct by itself and in combo with Merck’s CPI. That would put Merck in direct competition with part of the NEO trial that Advaxis has going with Amgen. See where I’m going with that?
News 
Market Data 
Discover 
